Atossa Therapeutics Inc logo

Atossa Therapeutics Inc (ATOS)

Market Open
15 Jun, 16:09
NASDAQ (CM) NASDAQ (CM)
$
2. 38
-0.08
-3.252%
$
21.18M Market Cap
- P/E Ratio
- Div Yield
209,227 Volume
-0.24 Eps
$ 2.46
Previous Close
Investors:
Analysts:
Add Transaction
Day Range
2.37 2.51
Year Range
2.36 19.35
Want to track ATOS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript

Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript

Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript

Seekingalpha | 3 weeks ago
New Strong Sell Stocks for Oct. 22

New Strong Sell Stocks for Oct. 22

ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.

Zacks | 7 months ago
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks | 1 year ago
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call.

Seekingalpha | 1 year ago
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.

Zacks | 1 year ago
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks | 1 year ago
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year.

Zacks | 1 year ago
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.

Zacks | 1 year ago
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice

Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice

Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.

Zacks | 1 year ago
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025

By now, you're well aware of the dangers of trading penny stocks with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here's what the U.S. SEC says: “ Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them.

Investorplace | 1 year ago
Loading...
Load More